Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Metabolism of [14C] CR845 in Hemodialysis Patients and Healthy Subjects
NCT03947970Phase 1Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of difelikefalin in chronic kidney disease (CKD), sponsored by Cara Therapeutics, Inc. Primary endpoints: Measure of [14C] CR845 and total radioactivity in plasma, urine, feces, and dialysate, Extent of recovery of [14C] CR845 and radioactivity related to [14C] CR845 and 3 more. Started Jan 2019; status: completed.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03947970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947970.